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Abstract 
 Human cytomegalovirus (CMV) is a widespread human herpesvirus responsible for a 
number of complications and diseases, particularly in immunocompromised individuals such as 
AIDS patients, organ transplant recipients, and patients undergoing treatment for cancer. 
Although there are antiviral compounds that have been approved for the treatment of CMV, there 
are a number of issues with these current drugs including limited bioavailability, significant 
toxicity, and high rates of resistance. Additionally, all of these drugs have the same target, the 
viral DNA polymerase. Thus, there is a need for new antivirals that have novel targets and lower 
toxicity. The herpesvirus alkaline nuclease, pUL98 in CMV, represents a potential novel target 
for the development of new antivirals. This protein is critical for efficient replication of the virus 
and has no closely related human homolog. The goal of this research was to purify and 
characterize active pUL98, which was then used to design a miniaturized, high throughput assay 
for screening potential inhibitors of the nuclease. A fusion construct consisting of a double 
histidine tag incorporated into the N-terminus of pUL98 facilitated purification of the protein by 
sequential passage over Ni-chelating and Mono Q anion exchange columns. Activity of the 
nuclease was confirmed using an assay measuring the ability to release soluble, radioactive 
nucleotides from uniformly labelled DNA. Several compounds have been identified via in silico 
modeling that are predicted to interact with and thus interfere with the active site of pUL98. Two 
of these compounds, Acid Blue 129 and Acid Blue 40, have been found to inhibit CMV 
replication. Using the newly designed assay, it was determined that Acid Blue 129 has a greater 
inhibitory effect on the nuclease activity of pUL98 (IC50= 9.3 μM) than does Acid Blue 40 (IC50-
= 149 μM). Both the new assay and in silico modeling to identify potential inhibitors of a protein 
were validated in the course of these experiments. Furthermore, inhibition of pUL98 may be the 
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mechanism by which Acid Blue 129, and the larger class of anthraquinone derivatives, has anti-
CMV activity. Further studies are needed to identify what genetic changes result in resistance to 
Acid Blue 129, thus elucidating the mechanism of inhibition.  
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Introduction 
Herpesviruses:  Impact on Health 
 Viruses are entities that identify, target, infect, and subvert the machinery of host cells in 
order to replicate and form new, infectious particles. A number of complications arise from viral 
infection of cells--directly as a consequence of host cell destruction and from the downstream 
effects of host infection and viral reactivation. Some of the more common viruses that impact 
human health are those of the order Herpesvirales, specifically the family Herpesviridae (Figure 
1). Those herpesviruses that infect humans are members of this family, and they are responsible 
for a number of diseases, issues, and complications in human health. There are eight human 
herpesvirus species comprising nine viruses, which include herpes simplex virus types 1 and 2 
(HSV-1 and HSV-2), Epstein-Barr virus (EBV), varicella zoster virus (VZV), human 
cytomegalovirus (CMV), human herpesvirus 6A, 6B, and 7, and Kaposi sarcoma-associated 
herpesvirus (KSHV),  otherwise known as human herpesvirus 8 (HHV8).  The specific effects of 
infection by a given virus depend on many parameters, including the site of infection, the age 
and immune competence of the infected individual, and whether the infection is due to a primary 
infection or one that results from reactivation of latent virus in that host.   
Herpes simplex virus types 1 and 2 (HSV-1/2) can have clinical presentations that vary 
greatly depending on these different factors—ranging from gingivostomatitis (cold sores), 
genital blisters (herpes labialis), and lesions on the fingers (whitlow), to life-threatening 
encephalitis, meningitis, or systemic herpes infection in neonates (9). Chickenpox, a common 
childhood illness, is the result of a primary VZV infection.  Reactivation of the virus in adults 
infected during childhood causes shingles, a painful disease that can leave lasting effects and 
neurological pain in patients (39).  EBV is commonly associated with infectious mononucleosis 
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in adolescents and adults (15), but also is linked to a variety of cancers such as Burkitt 
lymphoma, CNS lymphoma, and nasopharyngeal carcinoma (15, 16).  HHV8 is thought to be at 
least partially responsible for Kaposi’s sarcoma and other proliferative diseases in 
immonsuppressed men (35). As for many viral infections, the severity of these clinical 
manifestations is largely affected by the immune status of the host. Those individuals that are 
immunocompromised, whether from disease, medication, aging, or other causes, generally 
experience significantly more severe disease states (9, 35, 43). 
 Compounding the variety of different diseases and the associated viral-induced effects on 
human hosts is the prevalence of the different herpesviruses. HSV-1 and HSV-2 are quite 
common, and are estimated to infect between 65-90% of the world’s adult population (9). In the 
United States, the incidence of HSV-1 increases as an individual ages, from 26.3% at 6 years to 
90% in those 70 years or older (9).  For HSV-2, the incidence ranges from negligible to 20-40% 
at 40 years (9). The incidence of EBV is similar to that of HSV-1 with >90% infected by 
adulthood throughout the world (15). Of note is the fact that the exact prevalence of the different 
viruses varies by geographic region. KSHV is estimated to have a prevalence of 1-3% in North 
American blood donors but a prevalence greater than 70% in regions of Africa and in the 
Mediterranean where it is considered endemic (35). Thus, in both developed and developing 
countries, human herpesviruses have significant roles in the well-being of human populations. 
  It should be noted that herpesviruses infect animal hosts beyond humans.  There are over 
300 identified herpesviruses, the majority of which have only been discovered using PCR 
amplification (11). These herpesviruses infect a broad range of other organisms including rats, 
gorillas, sheep, cattle, primates, pigs, dogs, horses, fish, birds, and turtles (5, 12). The host range 
extends over most of the vertebrate lineage and even includes two herpesviruses found in 
McKee 5 
 
invertebrates (11). Even the non-human herpesviruses have an indirect effect on humans, as a 
number of the host organisms constitute livestock species of significant use and value.  
Classification of Herpesviruses 
Despite significant variations in host range, tropism, and clinical manifestation, there are 
unifying similarities between the different herpesviruses, the extent of which is determined by 
the taxonomic relationships between the different viruses. The structure of the herpesvirus 
infectious particle (virion) is conserved across all herpesviruses, and is the unifying characteristic 
defining Herpesvirales (11). Genetically, however, only two genes are homologous at the amino 
acid level across all members of Herpesvirales: DNA polymerase and the ATPase subunit of 
terminase (11). Among viruses, neither of these genes is unique to herpesviruses, though the 
ATPase subunit of terminase is the closest to being unique, as it is conserved only in T4-like 
bacteriophages in addition to herpesviruses (12). Analysis of the family Herpesviridae shows 
that a set of roughly 44 genes has been passed down from the common ancestor to the human 
herpes viruses, though some of these core genes have been lost over time in different viruses 
(11). Genes that are not part of this core generally represent gene products that allow the virus to 
occupy its specific niche (11).  
Based on recommendations of International Committee on Taxonomy of Viruses (ICTV), 
Herpesviridae can be further divided into three subfamilies that includes Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae (Figure 1) (12). HSV-1, HSV-2 and VZV are 
members of Alphaherpesvirinae (3). Human cytomegalovirus and human herpesviruses 6A, 6B, 
and 7 are members of the Betaherpesvirinae (3). The Gammaherpesvirinae subfamily contains 
EBV and KSHV (3). The ICTV constantly reevaluates the delineations and increasingly relies on 
DNA sequence comparisons to determine evolutionary relationships (10).  
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Figure 1 The phylogeny of the human herpes viruses. Within the order Herpesvirales, all human herpes viruses belong to the 
family Herpesviridae, which can be further subdivided into three separate subfamilies,  , and . 
 
General Structure and Replication of Herpesviruses 
 The Herpesviridae family of viruses are united not only by having a specific physical 
particle structure that is readily discernable by electron microscopy, but also by alternating 
between two kinds of life-cycles—1) productive replication, characterized by expression of most 
of the viral genes and usually resulting in the lysis of the infected cells, and 2) latency, 
characterized by a more restricted pattern of gene expression that fails to result in the production 
of infectious virions and which usually spares the cell from death (Figure 2). Additionally, many 
of the genomes of the herpesviruses share their overall architecture and are comprised of two 
different unique sequences, known as unique long (UL) and unique short (US), that are flanked 
by inverted repeats at both ends of each of the unique sequences (11, 40, 45). The region of the 
genome where a gene locus resides and its relative order within that region determines both the 
name of the gene and its protein (i.e. UL98 for the gene and pUL98 for the protein).  
 
 Herpesvirales 
Herpesviridae 
α 
 
HSV-1 
HSV-2 
VZV 
β 
 
CMV 
HHV 6a/6b 
HHV7 
γ 
 
EBV 
KSHV 
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Figure 2 Overview of the lytic and latent phases of the viral replication cycle. 1) The virus comes into contact with and specifically 
recognizes a host cell, enters the cell, and the nucleocapsid transfers its DNA to the nucleus. 2a) If the virus enters into the lytic 
pathway, it expresses most of the genes it encodes and replicates the genome.  Viral DNA packaging and virion maturation then 
occur. 3a) Production of the virus continues until the host cell lyses. 2b) If the virus enters into the latent pathway, the viral genome 
becomes associated with histones and remains largely quiescent. Only a limited set of viral genes are expressed and translated.  
Depending on the virus, the infected cells (such as neurons) do not divide and the viral genome remains. 3b) For other types of 
herpesviruses, the infected cell divides, but the viral genome replicates with cellular chromosomes, links to the chromosomes, and 
remains in cells following division. 3c) At times, the virus can be reactivated due to specific conditions in the cell or its environment. 
The virus then enters into the lytic pathway. 4) The viral progeny are released, and the process begins again. 
 
Structure of Virions 
 Herpesviruses share a specific set of core features that make up the structure of the virion. 
These include a double-stranded, linear DNA genome, the highly structured protein capsid 
surrounding that nucleic acid, the tegument, which are proteins that lie outside the capsid but 
within the outermost layer, and a lipid-containing envelope (Figure 3).  Compared to many other 
viruses, the size of the genome in these viruses is relatively large (3).  In addition to large 
genomes, herpes virions are also large in physical size — for example, virions of HSV-1 are 
1. 
2b. 2a. 
3b. 
3a. 
4. 
3c. 
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roughly 125 nm in diameter with a mass of about 200 MDa (8). The general characteristics of the 
capsid are conserved across the herpesviruses, at least in the Herpesviridae family (26). Each 
capsid has an icosahedral symmetry and is comprised of a number of proteins assembled into 
repeating units that compose the pentomers and hexomers (26). Unless specifically noted, all 
proteins in this section are referred to by their HSV-1 designation. Of the 12 pentomers at the 
vertices of the icosahedron, eleven of them are identical and are formed by the pUL19 subunit. 
The twelfth vertex is formed from a unique dodecameric portal complex containing the UL6 
protein, through which the DNA is inserted (8). pUL19 also serves as the main component of the 
150 hexomeric capsomers (the functional subunit of a capsid), with other proteins (e.g. pUL18 
and pUL38) linking the capsomers together (26).  
 The next layer of structure is comprised of a relatively large number proteins, and is 
known as the tegument (Figure 3b). This structure resides between the capsid and the membrane, 
and serves both regulatory and structural functions, including linking the capsid and the outer 
membrane together (26). Determining the exact functions of the tegument and its constituent 
proteins has been made very difficult for a number of reasons. First, the tegument itself, while 
containing conserved and critical protein components, is diverse in both structure and 
composition (8, 24). Furthermore, a variety of studies have shown that there is redundancy 
between different components of the tegument, making it difficult to elucidate their specific roles 
and whether they are absolutely required (24). It is known that there are two layers to the 
tegument—the inner layer, closest to the capsid, and the outer layer, which is adjacent to the 
outer membrane. Each of these layers contains specific proteins that are involved in a number of 
different functions. 
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 Finally, the outermost portion of a mature herpes virion is the envelope (Figure 3a). This 
structure is derived from a host cellular lipid bilayer membrane, and contains both viral and host 
proteins (24). The herpesvirus envelope is believed to potentially originate from the trans-Golgi 
network or related structures, such as ER-Golgi intermediates, depending on the virus (26). The 
most critical function of the envelope is recognition and attachment of the virion to the 
appropriate host cells via viral-encoded glycoproteins (24). However, the envelope also makes 
the virus more susceptible to inactivation via disruption of the lipid bilayer membrane. 
 
Figure 3 The structure of the herpes virion. There are various membrane-bound and transmembrane proteins that bind each layer 
to the other, as denoted by the black boxes connected by yellow lines. a) The outermost layer, the lipid envelope, is derived from 
the host cell. b) The layer deep to the lipid envelope is the proteinaceous tegument. While the functions of some of the proteins 
found here are known, many are not. c) Deep to the tegument is the capsid, comprised of a specific pattern of protein complexes. 
d) Within the capsid resides the viral DNA (much more DNA is packed into the capsid than pictured). 
 
Life Cycle of Herpesviruses 
  I will focus my discussion on the productive lytic cycle of herpes virus replication as this 
is the cycle that is targeted by antivirals and for which the best information exists.  Although the 
a 
d c 
b 
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discussion will focus on aspects of HSV-1 productive replication as a general model, when 
appropriate, homologous functions of other herpesviruses will be noted. 
 For a virion to successfully infect a host cell and produce progeny, it must first recognize 
and attach to a receptor present on the plasma membrane of the host cell (Figure 5a).  This 
attachment is mediated by glycoprotein components of the virion envelope.  These glycoproteins, 
including gB, gC, and gD in HSV-1, function in recognizing specific host cell receptors (24). 
The glycoprotein composition of each herpesvirus and the specific cognate cellular receptors 
determine both the host and tissue tropism of each virus.  Following attachment of the virion, 
some of the viral glycoproteins mediate fusion of the viral envelope and plasma membrane for 
entry of the capsid and associated tegument proteins (24). For HSV-1, alternate methods of entry 
involving pH-dependent entry via endocytic pathways also occur, though the specific method of 
entry depends on the cell type being infected (24). Following entry of the capsid and at least 
some of the tegument proteins into the cytoplasm of the host, many of the tegument proteins 
dissociate from the capsid due to their phosphorylation by viral and/or cellular kinases (8, 24). 
One of these kinases, pUL13, is conserved in the Herpesviridae family, and may play a similar 
role in the other herpesviruses (24). 
 The subset of the inner tegument proteins that remains attached to the capsid may 
perform certain key functions required in getting the viral capsid and its genetic payload to the 
nucleus (Figure 5b) (24). It has been proposed that some of the tegument proteins function in 
linking the capsid to the dynein/microtubule transport system, as evidenced by the physical 
association between inner tegument pUL35 and dynein (24). Two of the inner tegument proteins 
that remain associated with the capsid are pUL36 and pUL37, which are also conserved across 
Herpesviridae, suggesting a potential role in trafficking of the capsid (24).  No specific 
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interactions between pUL36 or pUL37 and dynein have been identified, however, so they may be 
involved in other functions (24). Some important differences in the apparent functions of these 
proteins or their homologs do exist between different viruses.  For example, the HCMV pUL37 
homolog, pUL47, is not necessary for entry and trafficking of the capsid to the nucleus (24).  In 
addition to a putative role in binding the dynein transport system, pUL36 is also believed to 
function in targeting the capsid to the nucleus, potentially by interacting in some way with the 
nuclear pore complex (24). pUL36 has been shown to have a nuclear localization signal 
sequence, consistent with a role in directing the capsid to the nucleus (24). It has also been noted 
that cleavage of the N-terminal end of pUL36 is followed by entry of the viral DNA into the 
nucleus, suggesting that pUL36 may play a role in injection of viral DNA into the host nuclear 
compartment (24). A second key protein believed to play a role in releasing the viral DNA from 
the capsid is pUL25, which may interact with the nuclear pore complex (8, 26). 
 Following entry of the viral DNA into the nucleus, several events must occur. These 
include transcription of viral genes, synthesis of viral proteins from these transcripts, replication 
of the viral DNA to amplify the genomes for packaging into capsids, and the beginning of virus 
capsid assembly (Figure 5c, d, e). Several components of both the virus and host cell are utilized 
in completing this process, which must occur before egress from the nucleus and maturation of 
the virion particle. Like many developmental systems, there is a pattern that emerges in the 
temporal regulation of herpes virus gene expression (24).  This regulation occurs coordinately 
and in a cascade fashion, starting with immediate-early gene expression to set the stage for 
replication (Figure 4) (24).  These immediate-early genes play primarily regulatory roles that 
serve to enhance viral gene expression and do not require the prior expression of viral protein 
(24).  Some (such as ICP4) are required by the subsequent wave of transcription of early genes, 
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many of which are required for the process of DNA replication and for the regulation of cell 
functions that are required for replication or which need to be subverted to permit replication or 
prevent cell death (24).  The last wave of gene expression leads to the synthesis of a variety of 
structural components of the virus (e.g. capsid proteins, envelope proteins, tegument proteins) as 
well as proteins that are required for the processing of replicated DNA and its insertion into 
empty capsids and their maturation (24).  
 Both tegument and capsid proteins have been shown to play a role in the regulation of 
gene expression, though they are not conserved across all herpesviruses, as some are only present 
in specific subfamilies (e.g. pUL48 in Alphaherpesvirinae members) (24). Expression of the 
early genes leads to the production of factors that initiate replication of the viral DNA as well as 
the expression of late genes, and which are also not conserved across all Herpesviridae family 
members (24). In addition to acting as regulators of transcription, some tegument proteins 
function at the level of regulating translation, either preventing the general synthesis of protein in 
the host (e.g. pUL41 endoribonuclease activity degrading both host and viral mRNA) or 
preventing host mechanisms from shutting down gene expression (e.g. ICP0 targeting cellular 
proteins such as interferon for degradation via ubiquitin ligase activity) (24). Still other tegument 
proteins play a role in replication of viral DNA, such as thymidine kinase (pUL23) and dUTPase 
(pUL50) which function in nucleotide metabolism in non-dividing host cells (24).  
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Figure 4 Overview of cascade expression in herpes viruses. These waves are often coordinated with each other and with the 
environment/host. This coordination can be regulated by protein interactions, signals, and other regulatory mechanisms. a) 
Initially, the first wave of genes (the immediate-early genes, in pale blue) will be expressed without any prior viral synthesis via 
proteins included in the capsid (at least in the case of HSV-1) (24). b) A second wave of gene transcription is triggered by the 
products of the first wave. These represent the early genes (in orange) in the herpes virus cascade. c) A third wave can be 
triggered by the products of the second wave. In herpes, these are the late genes (in green). d) Different protein products will play 
different roles in the life cycle of the virus. 
 
Herpesvirus DNA Replication 
 Shortly after the HSV-1 genome enters into the nucleus, the linear DNA circularizes, 
likely using host machinery (28, 40). DNA replication is carried out by a complex of proteins 
referred to as the replisome.  Though other proteins are likely to be present, the replisome 
contains six core viral-encoded proteins that are conserved across the Herpesviridae family (28, 
b 
a 
c 
d 
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40). The HSV-1 DNA polymerase holoenzyme is a heterodimer composed of two subunits, 
pUL30 (catalytic subunit) and pUL42 (processivity subunit) (40). A heterotrimer comprises the 
helicase-primase complex, and is made up of proteins pUL5, pUL8, and pUL52 (28). The final 
core protein is a single strand DNA binding protein designated as pUL29/ICP8 (40). There are 
additional proteins that play important and even, essential, roles in DNA replication that are not 
conserved across all herpesviruses. One of these proteins (for HSV-1 and HSV-2) is the origin 
binding protein (OBP), encoded by UL9 (28, 40). pUL9 binds specifically to regions of DNA 
that are known sites where DNA replication is initiated (origins) (28, 40).  HSV has 3 bona fide 
origins, though only 1 is necessary for DNA replication, at least in cell culture (40).  In the most 
accepted model for initiation of viral DNA replication, pUL9 both binds to and initiates DNA 
replication from origins, presumably by opening the duplex DNA using its helicase activity, and 
by permitting entry of the other replisome proteins through its ability to physically interact with 
the members of the aforementioned subcomplexes (28, 40). Activation of replication for certain 
other herpesviruses, such as HCMV and KSHV, is more complicated than for HSV-1 or HSV-2, 
and does not require the product of pUL9 or an ortholog  (40). For example, it is thought that 
transcriptional transactivators may be involved in initiation of DNA synthesis for some 
herpesviruses (40).   
 For HSV-1, replication occurs in defined locations within the nucleus, known initially as 
foci, which develop as time progresses into sites of localized replication, also known as 
replication compartments (28). The first step that must occur is activation of one of the three 
origins of replication present in the genome of HSV-1, which is carried out by pUL9 (OBP) and 
ICP8 (28, 40). These proteins bind to one or more of the origins and promote conformational 
changes in the DNA that cause the two strands to unwind at a defined location, allowing the 
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replication proteins access to the DNA (28, 40). It should be noted that this series of steps has 
been identified in an in vitro system, where a number of questions remain regarding the specific 
conditions in an infected cell and how synthesis is initiated in such an environment (28, 40). 
Following activation of the origin, the helicase/primase complex is recruited to the DNA, where 
it functions as its name suggests—the double stranded DNA is unwound and RNA primers are 
laid down in preparation for replication (40). Recent findings demonstrate that this complex may 
not exist simply as a trimer, but rather in some higher order structure that is important in the 
process of DNA replication (28, 40). It is worth noting that pUL8 has no recognized cellular 
homolog protein, and that the complex itself can be targeted by antivirals (28). Finally, the DNA 
polymerase complex is recruited to the DNA, likely through some conformational change in the 
higher order structure of the helicase/primase complex or by the presence of primer on the single 
stranded DNA (40). Thus far, no one has managed to recreate origin-dependent synthesis of viral 
DNA outside of cells, so the exact process that occurs intracellularly remains unclear (40). 
Replication of both the leading and lagging strands occur in the initial stages of replication, 
which is thought to occur via a theta-replication mode (28).  At later times, a second mode of 
replication is thought to ensue (via a rolling circle mode) which leads to the generation of long, 
head-to-tail concatemers (28). These concatemers must be processed to unit-length DNA 
genomes with specific ends that are packaged into nascent assembled, but empty capsids.  
 In addition to proteins that are directly involved in DNA synthesis, herpesviruses encode 
additional proteins, known as auxiliary proteins, which support virus replication, but are so 
named because they are not absolutely essential for viable virus production, at least in tissue 
culture or in some cell types (40). These proteins include thymidine kinase (pUL23), which 
functions in nucleotide metabolism by phosphorylating nucleosides (40). Another important 
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auxiliary protein is the nuclease pUL12, which contains 5’-3’ exonuclease activity and is 
required for replication of infectious virus in vivo (40). It should be noted that the alkaline 
nuclease is conserved across all herpes viruses, and its homolog in HCMV is designated pUL98 
(6, 18, 25). These auxiliary proteins have also been identified as targets for the development of 
antiviral drugs.   
Capsid Assembly 
 The final steps in the lytic life cycle are assembly and processing of virus structural 
components, maturation of the virion, and egress of the virus from the host cell (Figure 5f, g, h). 
The capsid is assembled inside of the nucleus and DNA is inserted into empty capsids in a 
coordinated fashion that involves interactions among concatemeric DNA, a complex of proteins 
called the terminase, and the unique vertex on virus capsids known as the portal (21). The 
process may have evolved from similar processes in certain bacteriophage (26). The major 
components of the capsid, pUL19, pUL18, and pUL38, are assembled into empty or pro-capsids 
and contain an inner scaffolding protein, pUL26, required for the DNA to be inserted (8, 26). It 
is proposed, but not proven, that the dodecameric portal complex, composed of pUL6 subunits, 
serves as a nucleation site for the auto-assembly of the procapsid (8, 21, 26). Following 
formation of the procapsid, pUL26, an autocatalytic protease, initiates cleavage of portions of the 
scaffold as the viral DNA is being packaged (8, 26).  
Several proteins are required for the proper packaging of viral DNA, many of which are 
conserved across the herpesviruses, including pUL15, pUL28, and pUL33, which form the 
terminase complex, and pUL17 and pUL32 (26).  Interestingly, pUL17 helps to recruit pUL25 to 
the capsid, where both of these proteins may be considered the beginning of the inner tegument, 
rather than capsid proteins (26). These proteins form a heterodimer that is believed to function in 
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stabilizing the capsid through their interactions with each of the capsid vertices (21). The 
function of pUL32 has not been fully identified, but it is thought to potentially play a role in 
proper localization of the capsid so that DNA packaging can occur (21). Again, the ATPase 
subunit of terminase, pUL15, is the most conserved gene in Herpesviridae, indicating a critical 
role in the life cycle of human herpesviruses (21). In vivo, pUL15 forms a heterotrimer with 
pUL28 and pUL33, to form the functional terminase complex (21, 38, 45). The complex forms in 
the cytoplasm and is subsequently localized to the nucleus of the host via a NLS encoded by 
pUL15 of HSV-1, while the terminase homologs in CMV require oligomerization for efficient 
localization (21, 38). Terminase is critical in the actual process of DNA packaging, as it forms a 
machine capable of inserting DNA into the capsid, despite the unfavorable interactions caused by 
tight DNA packing (21).  Terminase functions in recognizing unit length genomes in the 
concatemeric DNA that is formed during viral replication and in cleaving the DNA at specific 
signals to yield defined ends (45). Due to the difficulty of purification of the intact terminase 
complex because of its insolubility, the exact functions of each of the subunits is only beginning 
to be elucidated (21). As demonstrated by both Yang et al and Heming et al, mutations in key 
regions of HSV-1 pUL15 and pUL28 lead to loss of significant viral replication and improper 
DNA packaging and cleavage (21, 45). The role of pUL33 is not as clear, though it is believed to 
play a role in promoting the interaction between pUL15 and pUL28 (21, 38). The analogous 
genes in human cytomegalovirus are believed to be pUL89, pUL56, and pUL51 (pUL15, pUL28, 
and pUL33 in HSV-1, respectively) which are somewhat conserved in function (though not as 
much in sequence) but subtly different in some of their characteristics and interactions (38).  As 
the DNA is packaged into empty pro-capsids (also known as B capsids), the autoproteolytic 
pUL26 scaffolding protein is cleaved.  If the process is completed successfully with the 
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terminase cleaving the appropriate DNA end and “head-full” amount, the procapsid will undergo 
a conformational change to produce electron-dense complete capsids (also called C capsids).  If 
the process does not occur properly, the DNA will be exuded, leaving an empty capsid that lacks 
detectable intact scaffold (also called A capsids) (8, 45).   
Virion Maturation and Egress 
 To complete the entire replication cycle, the capsid must exit the nucleus and mature into 
an infectious virion containing tegument and an envelope (Figure 5f, g).   The generally accepted 
model of egress is known as the envelopment-deenvelopment-reenvelopment model (24, 26).  In 
this model, the nucleocapsid exits the nucleus by budding through the inner lamellae of the 
nucleus.  This enveloped nucleocapsid is not infectious, but subsequently fuses with the outer 
lamellae of the nucleus, forming the envelopment-de-envelopment steps of the model (8, 24, 26). 
The pUL17/pUL25 complex has been shown to be necessary for proper egress from the nucleus, 
and it is believed that pUL25 mediates interactions between the capsid and the inner membrane 
(8, 26). Whether or not pUL25 binds to other proposed nuclear egress proteins, such as pUL31 
and pUL34, is not clear (8, 26). However, the pUL31/pUL34 complex has been shown to be 
necessary for proper nucleocapsid budding (24, 26). The proper localization of the 
pUL31/pUL34 complex has been indicated as a role for the viral kinase pUS3, which also 
functions in phosphorylating the nuclear lamins A/C (24). Deletion studies show that the 
pUL31/pUL34 complex forms inappropriate aggregations in the absence of pUS3 (24).  
 Once in the perinuclear space, the enveloped nucleocapsid must fuse with the outer 
nuclear membrane to gain access to the cytoplasm of the host cell. It has been shown that pUS3 
is required for efficient movement of the particle from the perinuclear space to the cytoplasm, as 
loss of this kinase leads to accumulation of enveloped nucleocapsids between the outer and inner 
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nuclear membranes (24, 26). In addition, glycoproteins gB and gH, which are used in entry of the 
mature virus into host cells, have been implicated in playing a role in nuclear egress, though the 
specifics are not clear and much disagreement exists (24, 26). Studies have shown that nuclear 
egress and viral entry remain separate processes, and that the use of glycoproteins in exiting the 
nucleus may represent a virus or sub-family specific phenomenon (26). 
 The last steps include finishing tegumentation of the nucleocapsid and secondary 
envelopment (reenvelopment portion of the egress model), which occur in the cytoplasm of the 
host (Figure 5g). Some tegument proteins are thought to potentially be added prior to this step, 
while the capsid is still in the nucleus, though the data is contradictory (24). Regardless, it is at 
this point that the inner tegument proteins pUL36 and pUL37 are added to the nucleocapsid, as 
well as other proteins that may be specific to a particular herpes virus or to sub-family members 
(24, 26). The pUL36 protein is likely to be recruited via interactions with pUL25, which in turn 
recruits pUL37 (24, 26). Thus, it is proposed that pUL36 acts as a sort of “nucleation” point for 
the addition of inner tegument proteins, serving as a recruitment factor (26). Localization studies 
indicate that these proteins are added to the nucleocapsid at or near the Golgi (24). In addition to 
recruiting other tegument proteins, pUL36 is necessary for transport of the capsid to the correct 
cellular location for secondary envelopment (24, 26). Finally, pUL36 is proposed to play a role 
in linking the inner and outer tegument layers along with pUL48, contributing to the stable 
formation of mature virus (24, 26). Whereas the inner tegument is largely specific in the relative 
amounts of its constituent proteins, the outer tegument is much more variable, suggesting 
significant redundancy in function between many of the protein subunits (24, 26). A trimer 
composed of pUL11, pUL16, and pUL21 is believed to play a role in anchoring the tegument to 
the viral envelope, though the necessity of this complex varies among herpes viruses (24, 26). 
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Paralleling the ability of some tegument proteins to recruit other tegument proteins is the ability 
of the tails of some glycoproteins to recruit outer tegument proteins (26). Thus, addition of 
tegument proteins and maturation of the virion is a complex and multistep process. Many other 
studies have shown a variety of defects in packaging and maturation of the viral particles when 
various putative glycoproteins and tegument proteins are mutated or missing, but the exact 
function of these constituents and their addition to the virion is incomplete and lacking in detail 
(26). 
 Prior to release of mature virus from the host cell, the maturing nucleocapsid with 
associated tegument must acquire its final envelope (Figure 5g). Secondary envelopment likely 
occurs either within the trans-Golgi network or in an ER-TGN intermediate (26). The 
nucleocapsid, together with its tegument proteins, are thought to obtain their final envelope from 
TGN membranes containing viral glycoproteins (26). These forms are infectious and may be 
released into the cytoplasm in secretory vesicles capable of fusing with the plasma membrane to 
release the fully mature, infectious enveloped virus particle (Figure 5h) (26).   
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Figure 5 Summary of the lytic cycle for herpes viruses. a) The virion recognizes a host cell and can either fuse with the plasma 
membrane of the cell or be taken in via endocytosis mediated entry. b) Once inside the host, the capsid is transported to the 
nuclear membrane (the nucleus is in green), through which the viral DNA is injected. c) Once inside the nucleus, the viral DNA 
initiates cascade replication via the immediate-early genes. Subsequent expression produces mRNA that is transported to the 
cytoplasm. Concurrently, long head-to-tail concatamers of viral DNA are produced, which must be processed and properly 
packaged to produce fully mature capsids. d) Viral mRNA is produced in large amounts, siphoning ribosomes away from host 
translation. e) Some of the viral proteins are transported back into the nucleus, where they may act in a variety of ways. This 
includes roles as transcription factors, components of the capsid, and components of the viral replication and packaging 
machinery. f) After packaging, the mature capsid egresses into the cytoplasm. g) Further virion maturation occurs within the 
cytoplasm, where tegumentation is completed and envelopment occurs (believed to be derived from the Golgi apparatus). h) 
Viral replication and production continues until the host cell is compromised. Lysis of the cell releases the virions, and the 
process begins anew.  
 
a 
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Human Cytomegalovirus 
 At this point, I will now shift the focus of discussion from information about general 
herpesviruses to the prototypical member of Betaherpesvirinae and the subject of my research, 
CMV (27, 32). With a worldwide distribution, CMV is a ubiquitous pathogen that has a 
prevalence in human adult populations of anywhere between 40 and 100%, depending on 
geographic location, socio-economic status, age, sexual activity, and other related factors (32, 33, 
37). As with all herpesviruses, CMV establishes a latent infection following primary infection, 
and is capable of periodic reactivation. Latency is established within cells of the myeloid lineage, 
where CMV is present as an episome, an extrachromosomal piece of circular DNA that is 
maintained and persists throughout the lineage of its host cell (16, 33, 37). It has also been shown 
that CMV can be detected in the endothelial cells and epithelium of patients with active infection 
and that the virus can be grown in these cell types in vitro, though latency in these cell types has 
not been demonstrated (32, 33). Transmission is made possible following activation of the lytic 
life cycle through the shedding of virus in a variety of body fluids, including breast milk, semen, 
saliva, urine, cervical secretions, placental transfer, blood transfusions, and organs (through 
organ transplant) (33, 34). Close contact between individuals is generally required for 
transmission of the virus, usually from an asymptomatic individual who is actively shedding 
virus (16).  
The outcome of primary infection, reinfection, or reactivation is largely dependent on the 
status of the host individual—those that are immunocompetent are often either asymptomatic or 
mildly symptomatic while shedding virus, whereas those persons who are immunosuppressed 
can suffer a variety of diseases and pathologies (16, 27, 32, 34, 37). CMV is particularly 
associated with a reduction in and functional depression of T cells in host individuals (16, 33). 
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Thus, those persons who are infected with HIV and have AIDS, or individuals who are 
undergoing immune suppression (i.e. transplant recipients, cancer patients) are especially at risk 
of severe disease. The diseases that are associated with CMV active infection are numerous, 
devastating if untreated, and sometimes fatal. Some of these include pneumonitis, retinitis, 
gastritis, and colitis (33, 34). Some diseases are more prominent in different patient 
subpopulations. Retinitis makes up the vast majority of the manifestation of CMV infection in 
HIV patients (34). However, pneumonitis is exceedingly rare in AIDS patients coinfected with 
CMV, likely due to an interaction between the host’s immune system and CMV (33). In addition, 
CMV is the most prevalent and important congenital infection in developed countries, causing 
significant diseases and birth defects in neonates (7, 32, 36, 37). Among these are 
hepatosplenomegaly, jaundice, petechiae, microcephaly, mental retardation, and sensorineural 
impairment affecting vision and hearing (7). 
There are a number of other manifestations that have been shown to be associated with 
CMV but have not been confirmed to be caused by or a direct consequence of CMV. Many of 
these manifestations are believed to operate through host immune system interactions with 
CMV—manifestations which include autoimmune diseases such as Guillain-Barre syndrome, 
type I diabetes, systemic sclerosis, organ transplant rejection, and vascular disease (33, 34). 
CMV has a dynamic interaction with the immune system of its host, and contains many genes 
that have been shown to interfere with and alter the host immune response in vitro (7, 33, 37). 
Annotation of the CMV genome has either confirmed (19 genes) or led to the identification (14 
genes) of a number of different genes that interact with the immune system of the host in some 
way (37). Prominently, CMV interferes with antigen processing in immune cells by inhibiting 
the presentation of MHC class I molecules through the activity of a number of gene products 
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found in the unique short region of its genome (7, 33, 37). It is believed that CMV may also play 
a role in the down regulation of MHC class II genes in a similar manner (7, 33). Other 
interactions between CMV and host immune components have been characterized to lesser 
degrees, including various interactions with natural killer cells and dendritic cells, and the 
production of various small, chemokine-like molecules (7, 33, 37). These complicated 
interactions and pathways are proposed to play significant roles in the development of some of 
the autoimmune manifestations associated with CMV (33). 
More recently, CMV has been implicated in oncomodulatory roles in infected 
individuals, particularly those that are immunocompromised (13, 27). However, the precise role 
that CMV plays is debated, and no real consensus has been reached.  Some studies purport that 
CMV infection is cancer protective while others find no significant association between CMV 
and cancer progression (13, 27). Regardless, enough evidence exists that CMV has been 
examined as an agent in cancer development for several decades (27). While CMV cannot be 
regarded as a tumor virus, due to the complete absence of evidence indicating its ability to 
transform normal host cells, there are a number of associations that have been observed between 
CMV and cancer (13, 27). Antigens and nucleic acids belonging to CMV have been found within 
tumor tissues removed from patients, though the association has yet to be explained (13, 27). A 
recent study shows a correlation between active CMV infection and the onset of gastric cancer, 
though CMV as a causative agent of gastric cancers has remained hypothetical (13). The 
reservoir of data regarding the roles that CMV may play in cancer development and progression 
continue to be expanded, and are an important area of research. 
Antiviral Drugs that Combat Herpesviruses 
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 Due to their significant impact on human health, herpesviruses are one of the three major 
categories of virus for which there are available, targeted antiviral drugs (30). Since the 1960s, 
nucleoside analogues have served as the compound of choice for anti-herpesvirus drugs to viral 
replication and spread (14, 30). Currently, nucleoside analogues make up the vast majority of 
available herpesvirus antivirals, though there are some limited alternative drugs available. 
Additionally, there exists an effective vaccine for VZV that is used both in children and the 
elderly, populations that are at risk for chickenpox and herpes zoster, respectively (15). Vaccines 
for other human herpesviruses, however, are lacking; little success has been made with regards to 
vaccines against HSV (15). Some progress has been made with two different variants of a CMV 
vaccine, one of which contains viral proteins and the other which contains DNA plasmids that 
can express CMV genes (15). As for EBV, HHV-6, HHV-7, and KSHV, no vaccines are 
currently available (15).  
All of the currently approved antiherpes drugs used in the United States act by inhibiting 
replication of the virus, specifically by inhibiting the viral DNA polymerase (Table 1) (15, 30, 
41). Different compounds have varying efficacies against the different human herpesviruses. 
Acyclovir, penciclovir, and foscarnet are generally used against the alpha herpesviruses HSV-1, 
HSV-2, and VZV (15, 30, 41), while ganciclovir, cidofovir, and foscarnet are used to treat CMV 
(15, 19, 23, 30, 41). Currently, there exists no antiviral treatments for EBV, HHV-6, HHV-7, or 
KSHV (41). Valacyclovir, famciclovir, and valgancyclovir are the oral prodrug variants of 
acyclovir, penciclovir, and ganciclovir, respectively (15, 19, 23, 30, 41). These variants have 
significantly higher bioavailability via the oral route than their non-modified counterparts (15, 
30). Once in the body, the prodrug variants are converted back into their respective base 
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compound by host metabolic processes (16, 30). Thus, the mechanism of action for the prodrugs 
is the same as their base variants.  
Many of the antiherpes drugs share very similar mechanisms of action, though key 
differences exist for some of the compounds (Table 1). Acyclovir, penciclovir, and ganciclovir 
are all nucleoside analogues that must be converted into an active form by a combination of viral 
and cellular enzymes (15, 19, 23, 30, 41). In each case, the inactive drug must be initially 
phosphorylated by a virus-encoded kinase, thymidine kinase from HSV in the cases of acyclovir 
and penciclovir, and a protein kinase (pUL97 from CMV) in the case of ganciclovir (15, 19, 23, 
30, 41). The monophosphate forms of these compounds are then further modified by the cellular 
machinery of the host to produce the active triphosphate forms of the drugs (15, 19, 23, 30, 41). 
The active forms then function in inhibiting viral DNA replication by competitively binding to 
the active site of the viral DNA polymerase and terminating DNA elongation upon incorporation 
into the growing chain (15, 19, 23, 30, 41). Cidofovir has a bound phosphate group, thus 
eliminating the need for activation (formation of the monophosphate) via viral kinase activity 
(19, 23, 30).  This reduces the specificity of the drug’s action and results in the severe toxicity of 
the drug in humans.  Foscarnet is unique when compared to the other antiherpes drugs in that it is 
a non-nucleoside pyrophosphate analogue (19, 23, 30). Unlike the other compounds, foscarnet 
does not need to be activated via phosphorylation, instead inhibiting the viral DNA polymerase 
by competitively binding its pyrophosphate binding site and preventing the binding of incoming 
dNTPs (19, 23, 30).  
Acyclovir and penciclovir, the antivirals of choice for HSV-1 and HSV-2 infections, have 
a number of qualities that makes them particularly effective (15, 41). While all of the antiherpes 
drugs have some degree of toxicity, these two drugs have a well-established safety record (41). 
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Some of the more common adverse effects caused by these drugs include low rates of reversible 
nephrotoxicity, reversible neurological issues, and nausea (30). In general, the nucleoside 
analogues are safer and have lower toxicities than the other drugs due to several factors, 
including the necessity of a viral kinase for activation and poor inhibition of host DNA 
polymerases (15, 41). Additionally, the frequency of clinically relevant mutants resistant to these 
antivirals has remained relatively low at roughly 0.5% (15, 41). Though resistance does occur, it 
often results in a significant reduction of the virus to be able to replicate, causing it to become 
nonpathogenic (41). Current treatments for CMV, however, do not share these beneficial 
features, indicating a need for the continued development of new antiviral therapies. Due to the 
nature of the antivirals and their side effects, none of them are approved for treatment of 
congenital CMV infection (1, 2). Cidofovir (a nucleotide analog) has a higher toxicity than the 
nucleoside analogues, causing nephrotoxicity and myelosuppression (23, 30). Similarly, 
foscarnet is associated with significant toxicity, causing nephrotoxicity in 30% of patients, as 
well as electrolyte disturbances and neurological side effects (1, 30). The increased toxicity of 
these compounds is related to the fact that they do not need to be activated by viral protein, 
instead requiring only host proteins in the case of cidofovir or being functional without activation 
as with foscarnet (16). The drug of choice for combating CMV, ganciclovir, is associated with a 
number of toxic effects on the host. Most commonly, treatment with ganciclovir results in 
myelosuppression, though a number of other effects are possible including CNS toxicity, 
nephrotoxicity, gastrointestinal distress, and abnormal liver tests (1, 30). Clinical data shows that 
roughly 10% of patients must stop treatment, and that approximately 33% of patients must have 
their dosage adjusted, interrupted or discontinued (1, 41).  
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Unlike acyclovir and penciclovir, resistance of the target virus to ganciclovir occurs 
much more frequently (41). The development of ganciclovir resistant CMV occurs most 
commonly in individuals being treated with ganciclovir over a long period of time, as is the case 
with immunosuppressed individuals (1, 19, 23). Resistance occurs from mutations in either 
pUL97, the viral kinase, or pUL54, the viral DNA polymerase (1, 19, 23). Mutations in pUL97 
confer resistance to ganciclovir, as it is needed to catalyze the initial phosphorylation step, 
whereas mutations in pUL54 can confer resistance to ganciclovir, cidofovir, foscarnet, or some 
combination of these drugs (19). Studies have shown that resistance to ganciclovir and foscarnet 
develops in 13-27% and 37%, respectively, of patients exposed to the drugs for one year, with 
cidofovir believed to have similar resistance rates (19). If resistance does occur in a patient, 
current treatments include increased doses of ganciclovir or a combination of ganciclovir and 
either cidofovir or foscarnet, all of which are associated with significantly increased toxicity (19, 
23). 
The toxicity of current antiviral treatments for CMV coupled with increasing numbers of 
resistant strains have led to the investigation of a number of new compounds. One of these 
compounds is known as CMX001, an oral prodrug variant of cidofovir (1, 15, 19, 23). Having 
completed stage II clinical trials, CMX001 shows greater activity against CMV with a less 
severe toxicity profile (15, 23). Maribavir is an inhibitor of pUL97 that showed promise, 
progressing to phase III clinical trials (1, 19, 23). However, despite its increased safety relative to 
current treatments, maribavir failed the phase III trials due to lack of efficacy (1, 23). These two 
compounds still target either pUL97 or pUL54.  Thus, although they are safer than ganciclovir, 
GCV-resistant mutations in these genes often result in resistance to these compounds as well. 
Therefore compounds that affect novel targets are needed.  A few have been identified and are 
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currently being investigated. Letermovir, tomeglovir, and BDCRB are all compounds that inhibit 
viral replication by interfering with the terminase enzyme, the key component for proper 
packaging and cleavage of replicated DNA, and a target that is truly unique to viruses (15, 19). 
The need for additional antiviral drugs to combat CMV is still great, particularly those that 
function against novel and virus-specific targets. Though some compounds are being 
investigated for inhibition of terminase function, other targets exist that have the potential to be 
specific, safe, and effective. 
 
Antivirals 
 
Targets Some Common 
Side Effects 
Primary Use: Notes 
Acyclovir/ 
Valacyclovir (oral 
prodrug) 
Viral DNA polymerase-
- nucleotide binding 
site; requires 
monophosphorylation 
by viral enzyme 
Nephrotoxicity, 
neurological 
complications, nausea 
HSV-1, HSV-2, VZV Established safety 
record; reversible side 
effects; relatively low 
toxicity; low rates of 
clinically relevant 
resistant mutants 
Penciclovir/ 
Famciclovir (oral 
prodrug) 
Viral DNA polymerase-
- nucleotide binding 
site; requires 
monophosphorylation 
by viral enzyme 
Nephrotoxicity, 
neurological 
complications, nausea 
HSV-1, HSV-2, VZV Established safety 
record; reversible side 
effects; relatively low 
toxicity; low rates of 
clinically relevant 
resistant mutants 
Ganciclovir/ 
Valganciclovir (oral 
prodrug) 
Viral DNA polymerase-
- nucleotide binding 
site; requires 
monophosphorylation 
by viral enzyme 
Myelosuppression, CNS 
toxicity, gastrointestinal 
distress, abnormal liver 
tests 
CMV Higher toxicity than 
acyclovir and 
penciclovir; high rates 
of resistant mutants 
Cidofovir Viral DNA polymerase-
- nucleotide binding site 
Nephrotoxicity, 
myelosuppression 
CMV Does not require 
activation by viral 
enzyme; significant 
toxicity 
Foscarnet Viral DNA polymerase-
- pyrophosphate binding 
site 
Nephrotoxicity, 
neurological 
complications, 
electrolyte disturbances 
HSV-1, HSV-2, VZV, 
CMV 
Active without 
activation by viral 
enzyme; significant 
toxicity 
Table 1 Overview and summary of the antivirals used to combat herpes viruses. 
Alkaline Nucleases 
 One such target for novel antivirals is the herpesvirus alkaline nuclease. Conserved 
across the Herpesviridae family, the nuclease is a member of the λ exo DNase family of proteins, 
within the PD-(D/E)XK superfamily of DNA-modifying enzymes (6, 17, 25, 31). Elucidation of 
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the evolutionary relationship between various enzymes within this superfamily shows that phage 
and virus nucleases originate from a single ancestor (6). Subsequent divergence and host-specific 
evolution has led to a low level of sequence similarity between the various proteins in this family 
(6). However, conservation of the putative active sites of these enzymes has allowed their 
relationships to be deduced despite differences in their presumed structure (6). These differences 
in structure give the various enzymes their substrate specificities, as evidenced by the necessity 
of particular N and C-terminal domains in the HSV and EBV nucleases that allow them to bind 
to DNA, which are absent in the λ nuclease (6).  
 Despite years of study and knowledge of its evolutionary history, the exact in vivo role(s) 
of the herpesvirus nuclease remain unknown, though its conservation in Herpesviridae provides 
one reason to believe that it serves an important role (18). In vitro, the nucleases have both 5’-3’ 
exonuclease and endonuclease activities, with the exo activity capable of degrading both single 
and double-stranded DNA (20, 25, 29, 31, 42). These enzymes exhibit a high pH optimum 
(alkaline), require the binding of a divalent metal cation (Mg2+), do not require ATP, and are 
inactivated at high concentrations of salt (20, 25, 29, 31, 42). Several studies using pUL12, the 
HSV-1 alkaline nuclease, have been performed, providing an indication of the role that the 
alkaline nucleases may play in vivo. It is known that pUL12 localizes to the nucleus of the host 
cell and that it is present at early times following infection (20). Resolution of HSV-1 replication 
intermediates by electrophoresis following digestion with restriction enzyme shows that in 
pUL12 null mutants, the DNA intermediate is even more complex than the wild type 
intermediates (20). Additionally, lacZ insertional mutants, which inactivate pUL12, lead to a 
significant decrease in plaque formation with only a small amount of infectious virus production 
(42). However, these mutants show little reduction in DNA or protein synthesis, indicating that 
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pUL12 is in some way required for efficient virion production but is not necessary for viral 
macromolecular synthesis (42). Further investigation of the role of pUL12 revealed that it is the 
loss of nuclease activity, specifically exo activity, which resulted in the inability of mutant 
variants of UL12 in plasmids/amplicons to complement null mutants and restore wild type viral 
production in cell culture (20, 22). Continuing along this line of thought, a recent study 
characterized the role of the nuclease activities of pUL12 with regards to viral replication and 
neurovirulence using recombinant virus (17). It was discovered that the nuclease activity of 
pUL12 was not actually required for replication of the virus in cell culture, but that it is 
necessary for virulence in a mouse model (17). Thus, there may exist another function for 
pUL12, independent of its nuclease function, which is critical in the life cycle of HSV-1 (17). 
Other experiments have shown that pUL12 associates with ICP8 and that in combination these 
proteins can catalyze strand-exchange in vitro (29). This led to an exploration of the possibility 
that pUL12 may function in some sort of recombination pathway, though subsequent studies 
showed that pUL12 is not necessary for neither intra- nor intermolecular recombination (29). 
 In summary, decades of research, while unable to elucidate the actual role that pUL12 
plays in the HSV-1 infection cycle, have revealed many facets to this enzyme. These 
experiments have led to a number of proposed functions for pUL12 that have changed slightly 
with time. Current theories hypothesize that the protein plays some sort of role in resolving 
complex, highly branched replication intermediates (18, 20, 29, 31), aids in the formation of 
capsids (17), or has an undiscovered function (17).  
While the majority of the research has been performed with pUL12, these hypotheses 
apply to other herpesvirus alkaline nucleases as well. This includes the pUL12 homolog found in 
CMV, the alkaline nuclease pUL98 (18). As mentioned, the herpesvirus alkaline nucleases, while 
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conserved, have low levels of homology—pUL98 is roughly 22-26% identical and 47% similar 
to pUL12 (18, 31). However, the active site residues have remained well conserved across the 
herpesviruses, and any other changes in adjacent domains likely reflect evolutionary pressures 
and substrate specificity (6, 25). pUL98 is a 65 kDa nuclease with the same reaction conditions 
and optima as the other herpesvirus alkaline nucleases (25, 31). Using the crystalline structure of 
KSHV alkaline nuclease, KSHV-SOX, which has been identified as the closest match to pUL98, 
a predicted model of pUL98 has been created (25). Subsequent analysis revealed two different 
binding sites, one of which is the active site with an adjacent binding site for the 5’ phosphate of 
the DNA substrate (25). However, the presence of a ‘bridge’ region in KSHV-SOX has limited 
the utility of this model as a substitute for the structural model of pUL98, indicating a need for 
resolution of the crystal structure of pUL98 (25).   
Several experiments and findings corroborate the evolutionary relationship and potential 
analogous roles of HSV-1 pUL12 and CMV pUL98. It is known that like pUL12, pUL98 can 
localize to the nucleus of host cells independently of other viral proteins, indicating that the 
protein sequence itself contains the necessary information for transport to and retention within 
the nucleus (18). Similarly, pUL98 can be detected early after infection, with a drastic increase in 
concentration following the onset of replication of the viral genome (31). Mutagenesis studies 
based off of the pUL98 structural model have identified the catalytic residues necessary for both 
the exo and endonuclease activities of pUL98 (25). Identification and analysis of the effects of 
mutations in these residues will allow for a greater understanding of the role of pUL98 in CMV 
infection. Initial experiments investigating the effect of a pUL98 null mutant either inactivated 
pUL98 via transposon insertion or removed UL98 and replaced it with galK.  In both cases, the 
changes resulted in lethality (25). However, these mutations could have affected adjacent viral 
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genes, and so an amber nonsense mutation was introduced that maintained the ORF (25). This 
revealed that, similar to pUL12, pUL98 is not absolutely necessary for viral replication, though 
the mutant virus was significantly impaired.  Although wild type CMV could be detected at a 
p.f.u. mL-1 of 104 by 33 days post infection, the amber mutant virus was not detected until 33 
days post infection (25). Despite the differences between pUL12 and pUL98, it has been shown 
that pUL98 can complement the lacZ insertional UL12 HSV-1 mutant (18). These findings 
indicate that pUL98 and pUL12 may serve similar roles, and that inhibition of pUL98 may result 
in the ability of the host to clear CMV infection due to attenuated replication of the virus. 
Additionally, pUL98 represents a different antiviral target that is not affected by current 
antivirals, and so resistance to currently used compounds is not likely to cause resistance to 
compounds inhibiting pUL98. Due to the evolutionary history of pUL98, it does not share 
homology with any known host enzymes, thus suggesting that any active compounds will be 
unlikely to interfere with host machinery, reducing the possibility of toxic effects of treatment. 
New Developments and Project Goals 
 Several decades ago, the search for new anti-HIV compounds led researchers to discover 
a number of potential antiviral compounds (4). One group of these compounds, anthraquinones, 
were found to have inhibitory effects on HSV-1 and 2, EBV, and CMV (4). This led to 
investigations on the effectiveness of anthraquinone derivatives, such as sulfonated 
anthraquinones, that had altered properties such as increased solubility (4). In addition to these 
altered compounds, other researchers looked at various anthraquinones that were isolated from 
different sources, such as rhubarb (44). Of the anthraquinones derivatives, several were found to 
be effective against CMV, including acid blue 129, acid blue 40, and alizarin violet R (4). 
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Another anthraquinone, emodin, was found to be active against HSV, potentially by inhibiting 
pUL12 (44).  
 This has led a research group composed of scientists from Virginia Commonwealth 
University and The Ohio State University, of which I am a member, to examine the effectiveness 
of the above listed compounds in inhibiting CMV (2). The research not only examined the 
effectiveness of the compounds in inhibiting viral replication and production in cell culture, but 
also the toxicity of the compounds to host cells (2). My main role in the recently published paper 
was to purify active CMV pUL98 and to setup, analyze, and determine the effectiveness of a 
miniaturized assay that would function in identifying other inhibitors of the CMV alkaline 
nuclease. In doing this, I examined the effects of acid blue 129 (atanyl blue PRL) and acid blue 
40 on the enzyme activity of pUL98 (2). The remainder of this thesis will cover the work that I 
performed, the conclusions that were reached, and the future directions that this line of research 
can produce. 
Materials and Methods 
Gene Construct and Plasmid Construction 
See Kuchta et al (25) for information regarding the construction of the plasmid. The 
double histidine tag and TEV cleavage site were both additions performed by Yali Zhu of the 
Deborah Parris research laboratory. Additional information regarding their construction can be 
obtained via correspondence. 
Transformation of BL21 (DE3) pLysS 
The transformation procedure used was the recommended method provided by Bioline. 
After thawing on ice, 50 µL aliquots of bacterial cells were mixed via light agitation. To these 
aliquots, 2 µL of pDest17 UL98 plasmid was added and subsequently mixed and incubated on 
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ice for 30 minutes. Heat shock (exposure to a 42 °C water bath for 30-45 seconds) was used to 
induce transformation of the bacterial cells. Following this step, the cells were cooled on ice for 
2 minutes. 
The transformed bacteria were then diluted to 1 mL by the addition of SOC media (2% 
tryptone, 0.5% yeast extract, 0.4% glucose, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4). Following dilution, each sample was incubated at 37 °C for 1 hour while shaking at 
225 rpm. Various quantities of transformed bacterial cells (10-200 µL) were used to inoculate 
Luria broth (LB)/ampicillin (1 µg/mL) agar plates. The plates were incubated overnight at 37 °C. 
Expression of pUL98 
Colonies grown on the LB/ampicillin agar plates were examined, and one colony was 
selected and inoculated into 50 mL of LB with ampicillin at a final concentration of 1µg/mL. 
The culture was then grown overnight at 37 °C while shaking at 225 rpm. The next morning, 20 
mL of this culture was used to inoculate 1 liter of LB, also with a final ampicillin concentration 
of 1µg/mL. This culture was incubated at 37 °C while shaking at 225 rpm until the cells reached 
OD of 0.6-0.8. At this point, the 1 liter culture was induced with 1 mL of 1M IPTG (final 
concentration 1 mM), and transferred to a room temperature water bath for 5 minutes. The 
culture was then incubated at room temperature while shaking at 225 rpm for 3 hours.  
After induction, the cultures were centrifuged at 4,000 g for 10 minutes at 4 °C. The cell 
pellets were then washed with 5x protease inhibitors in 5 mL of PBS and re-centrifuged for 10 
more minutes at 4,000 g. These washed pellets were then snap frozen in liquid nitrogen and 
stored in a -80 °C freezer. 
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A second 1 liter culture was induced with 20 mL of the overnight culture once the first 
culture was induced. Thus, each expression procedure resulted in the production of 2 liters of 
cells. 
Purification of pUL98 
 Each pellet from the expression assay was suspended in 10 mL of lysis buffer (20 mM 
Tris-HCl, 300 mM NaCl, 10 mM imidazole, 10% glycerol, 1% NP-40, 0.015% BME (15 
µL/100mL buffer), pH 8.0) containing 5x protease inhibitors and PMSF (5x). Pulse sonication 
(10-15 seconds over a period of roughly 10-15 minutes on ice) was then used to burst the cells. 
Samples were centrifuged at 70,000 g for 20 minutes at 4 °C. The supernatant was retained for 
purification. 
 Purification of the supernatant occurred over two steps: passage over a Ni-NTA column 
followed by passage over a Mono Q anion-exchange column. An AKTA fast protein liquid 
chromatography system using a preset program designed by an earlier member of the Parris lab 
was utilized. Samples were loaded onto the 5 mL Ni-NTA column equilibrated in lysis buffer 
and then washed with 40 mL of wash buffer (20 mM Tris-HCl, 300 mM NaCl, 20 mM 
imidazole, 10% glycerol, 0.015% BME, pH 8.0). Elution was carried out using a linear gradient 
of 60 ml transitioning from the wash buffer to the elution buffer (20 mM Tris-HCl, 300 mM 
NaCl, 1M imidazole, 10% glycerol, 1% NP-40, 0.015% BME, pH 8.0), creating an imidazole 
gradient of 20-500 mM. Those fractions that contained pUL98 by identification using anti-
pUL98 I-2 antibody were then pooled and dialyzed overnight in buffer B2 (20 mM Tris-HCl, 50 
mM NaCl, 1 mM EDTA, 10 % glycerol, 0.015% BME, pH 8.2). 
 For the Mono Q column, a different program designed by an earlier member of the Parris 
lab was utilized. The dialyzed Ni-NTA sample was loaded onto the 1 mL Mono Q column and 
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washed with 10 mL of buffer B2. Elution was carried out using a linear gradient of 25 mL of 
buffer B2 containing 0-500 mM KCl. To those fractions containing or suspected to contain 
pUL98 was added 2x protease inhibitors. 
 Identification of fractions containing pUL98 was done using three different criteria. First, 
the fractions could be run using SDS-PAGE and stained with Coomassie to visualize the 
different protein bands. The second method was to perform a Western Blot using the anti-pUL98 
I-2 antibody, which specifically marked pUL98 regardless of the presence of other protein. 
Finally, a radioactivity assay was used to measure the nuclease activity present in each fraction.  
Radioactivity Assay 
 One of two assays used to measure the nuclease activity in the different fractions 
obtained from purification is the radioactivity release assay. This assay is based on the method 
used by Hoffman and Cheng (2, 22). In particular, this assay does not discriminate between the 
exonuclease and endonuclease mechanisms of action. Activity of a sample was measured as the 
release of trichloroacetic acid-soluble radioactivity from E. coli dsDNA uniformly labelled with 
14C. In order to standardize results, a unit of activity was defined as the amount of enzyme 
necessary to digest 1 ng of substrate to solubility in 10 minutes at 37 °C. 
 Individual reactions were comprised of buffer, enzyme, and substrate, totaling 200 µL in 
volume. The buffer used consisted of 0.05 M Tris-HCl pH 9.0, 6 mM MgCl2, 1 mM DTT, 
0.0162 mg 14C DNA/mL, 0.2 mg/mL BSA, and water. For each reaction, 10 µL of enzyme was 
assayed (~1100 units). Prior to the addition of enzyme, the reaction buffer was incubated for 5 
minutes at 37 °C. Once the enzyme was added, the reactions were carried out for X minutes. The 
default length of time is 10 minutes, though some time courses were also performed. Water was 
used in the place of pUL98 for the control reactions. The reactions were stopped via the addition 
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of 50 µg of unlabeled, sheared salmon sperm DNA and TCA (final concentration to 5%), and 
subsequently sat on ice for at least 5 minutes. The reaction mixtures were then spun in a tabletop 
centrifuge at 3000 rpm for 10 minutes. To a scintillation vial was added 7.5 mL of scintillation 
fluid, 75 µL of 1.2 M NaOH, and 200 µL of the supernatant. The radioactivity was then 
measured using scintillation spectrometry. 
Zen Substrate 
 A 29-mer oligonucleotide was designed for use in a FRET assay capable of detecting the 
exonuclease activity of pUL98. The DNA strand forms a hairpin with a 5 bp overhang at the 5’ 
end of the molecule. Bound to the 5’ nucleotide is a FAM fluorophore, while an Iowa Black 
quencher is affixed to the 3’ nucleotide. Between nucleotides 9 and 10 is a proprietary compound 
known as Zen that is used to minimize background fluorescence even more than with the Iowa 
Black alone (IDT).  
 The material provided by IDT was diluted 1:10 (final concentration 10 µM) using buffer 
EB (10mM Tris-HCl, pH 7.5) (Qiagen) and then heated to 95 °C in a water bath for 2 minutes. 
The substrate was then allowed to cool slowly to a temperature of ~70 °C. After reaching this 
temperature, the material was quenched on ice and then stored at -20oC. Subsequent use required 
that the material be thawed in the dark and then distributed to the appropriate reaction vessels. 
FRET Assay 
 The buffer used for the FRET assays was similar to the buffer used in the radioactivity 
assays, and contained 0.05 M Tris-HCl pH 9.0, 6 mM MgCl2, 1 mM DTT, 0.2 mg/mL BSA, and 
water. However, they also contained 400 nM Zen substrate as well as 5% DMSO. The potential 
inhibitors to be tested were dissolved and stored in 100% DMSO and diluted to a final 
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concentration of 5% prior to their use in inhibition studies. If no inhibitors were being used, 5 µL 
of 5% DMSO was added instead.  
 For each FRET assay, the reactions were set up so that each vessel contained all of the 
components of the buffer, the Zen substrate, and the inhibitor (or control 5% DMSO), totaling 90 
µL in volume. The suspensions were then incubated for 5 minutes at 37 °C prior to the addition 
of 10 µL of pUL98. In place of pUL98, 10 µL of 1 mg/mL BSA was used in the control (no 
enzyme) reactions. The length of the reaction was altered based on the goals of the experiment. 
Many of the assays involved time courses, and so samples were run for 10, 30, 45, and 60 
minutes, for example. To stop the reaction, EDTA was added to a final concentration of 
approximately 12 mM.  Fluorescence was measured using a SpectraMax M5fluorometer 
(Molecular Devices), using 384-well plates containing 20 µL aliquots in triplicate from each 
reaction vessel. Background values obtained from the no enzyme control reactions were 
subtracted from the experimental readings to obtain relative fluorescence units (RFU).  
Inhibition Assays 
 The FRET inhibition assays were set up and run in the same manner as described above. 
Instead of using 5 µL of 5% DMSO, 5 µL of inhibitor was added to obtain the final 
concentration being assayed. Experimental readings were also obtained in the same manner. 
Activity levels were determined as a percentage of the maximum activity displayed by untreated 
controls (no inhibitor present). From these data, the 50% inhibitory concentration (IC50) values 
were obtained using a four-parameter function. 
 Radioactivity inhibition assays were set up using the same system as presented earlier, 
only with the addition of DMSO to a final concentration of 5% and the addition of inhibitor to 
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the desired final concentration. Experimental readings were obtained using the same method as 
described. 
Experiments and Results 
Gene Construct 
 The gene construct used in the following experiments consisted of the wild type UL98 
gene spliced to a double Histidine tag at its N terminus (Figure 6). The histidine tag is comprised 
of two stretches of six histidine residues separated by a short stretch of amino acids. In the linker 
region between the tag and UL98, there is a tobacco etch virus (TEV) cleavage site. This 
facilitates the removal of the histidine tag following purification of the protein. In the findings 
presented here, the tag was not removed, as the nuclease retained significant activity even in the 
presence of the extra tag domain. The gene construct was then inserted into the Gateway 
destination vector pDest17 (Invitrogen) for use in transformation and expression procedures. In 
this system, the gene is under control of a T7 inducible promoter. Further information regarding 
the construction of the plasmid and gene can be viewed in the Materials and Methods. 
 A double histidine tag was utilized in order to optimize purification of the pUL98 
alkaline nuclease. In the first phase of purification, described later, the bacterial cell lysate was 
passed over a Ni-NTA column. Histidine has a high affinity for this particular matrix, facilitating 
the purification of tagged pUL98. The tag is also small enough that it was predicted to not impact 
the folding of the protein or its activity, which was confirmed in later experiments. Thus, the 
construct would allow for rapid purification of pUL98, while providing a way to remove the 
protein tag should it impact enzymatic activity. This method was similar to the one used by 
Kuchta et al, though a single hexahistidine tag was used in those experiments (25).  
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Figure 6 Structure of the UL98 Gene Construct. The protein product of this construct is 623 amino acids in length, and has a 
molecular weight of 70.1 kilodaltons. The ORF, when in the pDest17 vector, runs from nucleotide 101 to nucleotide 1969. 
Removal of the histidine tag would have taken place had the protein shown reduced or no functional activity. Additionally, 
removal of the protein tag would be necessary for any further crystallography studies using this expression system. 
 
Expression of pUL98 
 The initial expression system was based off of work done by Allison Kuchta and her 
colleagues (25). BL21 (DE3) pLysS cells were transformed with the expression vector and 
cultured according to the Materials and Methods. Initially, in order to determine the most 
efficient conditions for protein production, a culture of E. coli cells was grown to an O.D. of 0.6-
0.8 and then exposed to IPTG to induce pUL98 expression. The protocol used by Kuchta stated 
that the culture was to be incubated for three hours after induction. To test this, aliquots were 
removed every hour until a total of four hours had passed. The bacterial cells in each of these 
aliquots were lysed and centrifuged, and the protein produced by the cells, both soluble and 
insoluble, extracted. The extracted protein was then analyzed on denaturing-polyacrylamide gels 
followed by staining with Coomassie blue (Figure 7). 
 Figure 7A shows the soluble protein profile of the bacterial cells when uninduced and at 
several time points following induction. Similar data is presented Figure 7B, though this contains 
the insoluble protein fraction. Over the course of four hours, the total amount of protein 
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produced increased with time as expected. By comparing the soluble fraction to the insoluble 
fraction, it can be seen that the majority of the protein remained soluble.  
 The pUL98 protein is predicted to have a molecular weight of 70.1 kDa, and so this 
served as the starting point for identifying the production of this protein. The marked region of 
the gel in Figure 7A indicates the expected position of a band corresponding to pUL98. Though 
the upper and lower bands have apparent molecular weights of 103 and 90 kDa respectively, this 
does not mean that pUL98 is not present. It is possible that the band corresponding to pUL98 
cannot be visualized well using Coomassie staining due to low concentrations of pUL98 
compared to other proteins in the sample. Additionally, my principle investigator, Dr. Parris, 
pointed out that in her own research on the HSV-1 DNA polymerase, it is observed that the 
polymerase migrates at a higher apparent molecular weight than expected due to the composition 
of the protein. A similar case could be occurring here. Worth noting is the fact that very little 
protein is revealed in the same region of the gel in Figure 7B, indicating that most of the protein 
at this approximate size is soluble. Thus, there was evidence showing that the protein of interest 
could be within the soluble protein fraction, justifying purification. 
 Using these data, it was decided that all subsequent expression experiments would be 
performed using a post-induction incubation time of three hours. In comparing the different lanes 
in Figure 7A, there is more darkly staining material present in the 3 and 4 hour post-induction 
lanes than in the earlier lanes, indicating the presence of greater amounts of protein. Three hours 
is preferred over four hours for three reasons. First, as cell density increases and bacteria begin to 
enter stationary phase, it becomes more difficult to lyse the cells and extract protein. Second, 
bacterial cells do not have a separate compartment for their genetic information. The protein of 
interest, being a nuclease, is thus toxic to the bacterial cell. This is the reason that BL21 cells 
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were utilized, as they keep background expression of genes under control of the T7 promoter low 
until induced by IPTG. In order to minimize the effect of this toxicity, the bacterial cells should 
be cultured long enough to obtain adequate amounts of protein and no longer. Finally, as the 
amount of protein produced by the bacterial cells increases, there is a greater chance of protein 
crystallization and precipitation. 
 A comprehensive analysis to determine the optimum conditions for efficient expression 
of pUL98 was not performed. Such an analysis would be necessary for future work involving 
production of pUL98 for crystallography studies.  
 
 
Figure 7 Coomassie Staining of Protein Extracted from E. coli Cultures. A) The upper and lower protein bands within the 
box have apparent molecular weights of 103 kDa and 90 kDa. The star indicates that 3 hours post-induction represents the time at 
which all subsequent purifications were performed. B) There is very little protein that is showing within the boxed region, 
especially when compared to the darkly staining low bands at ~35 kDa. 
 
Purification of pUL98 
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 Cultures were centrifuged, snap frozen in liquid nitrogen, and stored in a -80°C freezer 
for up to several months until purification procedures were executed. Frozen aliquots were 
suspended in lysis buffer, subjected to ultrasonic disruption, and the insoluble material removed 
by centrifugation. Sequential Ni-chelating and a Mono Q anion exchange columns as described 
in the Materials and Methods were used to purify pUL98. 
 In order to obtain purified pUL98, it was necessary to determine which elution fractions 
contained the protein. During passage of the sample over the Ni-chelating column, the elution of 
protein could be observed via a change in the optical density of the eluent. This information 
directed our attention to specific fractions being collected from the column. Initially, the 
presence or absence of pUL98 was determined via Coomassie staining and Western Blotting 
(Figure 8). 
 Those fractions that contained protein, as determined by their optical density, had to be 
analyzed to determine whether or not the eluted material included pUL98. Coomassie staining of 
the relevant fractions, as well as several preceding and succeeding fractions, was utilized to 
probe for the presence of pUL98 (Figure 8A). The boxed region in Figure 8A contains two 
different protein bands at apparent molecular weights of 88 and 78 kDa. Included in this data are 
the Ni-chelating column input and the collected flow-through (unbound), which appear almost 
identical (as is expected for a column with affinity for His tags specifically). Little to no protein 
can be visualized in the fractions flanking the lanes corresponding to fractions 31, 32, and 33.  
 The predicted size of pUL98 and whether or not there were protein bands corresponding 
to this size was used as criteria for determining whether or not the fraction contained pUL98 in 
early purifications. Protein bands such as those in Figure 8A were considered to be indicative of 
containing pUL98. Though the bands do not match the exact size of pUL98, they are close 
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enough in apparent size that further purification and analysis of those fractions was warranted. 
Furthermore, these fractions corresponded with the change in optical density observed during 
elution of the sample from the column (data not included). Samples that were suspected to 
contain pUL98 were pooled, dialyzed, and subsequently passed over the Mono Q anion 
exchange column (see Materials and Methods).  
 Protein elution from the Mono Q column could be observed through a change in the 
optical density of the fraction, as was the case with the Ni-chelating column. This again directed 
attention to particular fractions that were then analyzed by both Coomassie staining and Western 
blotting. Figures 8B and 8C present two different Western blots, each of which utilized a 
different antibody. In Figure 8B, an antibody that specifically recognized the His tag was utilized 
while an antibody specific to pUL98 was used in Figure 8C. While each lane containing a 
sample from a Mono Q fraction contains a signal in Figure 8B, so too does the lane containing 
the molecular ladder. In contrast, in Figure 8C, the lane containing the molecular ladder does not 
display any signal. However, the antibody to pUL98 also shows signals in each of the lanes 
corresponding to a different Mono Q fraction. Included in these data is a Mono Q input sample, 
which displays several signals at varying molecular weights.  
 It was initially planned that only the commercially available His antibody would be used 
to perform Western blots and to track the His-tagged pUL98. However, it was immediately clear 
that the antibody had poor specificity. The marker lane should not contain any of the antibody 
signal as none of the included proteins contain a His tag, yet that is exactly what is observed in 
Figure 8B. Since conclusive evidence demonstrated this nonspecificity, any other signals 
observed in blots using the His antibody could not be considered signals marking the presence of 
pUL98. This led to the use of the pUL98 antibody, which demonstrated a much better specificity 
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and allowed for clear determination of fractions containing pUL98 (Figure 8C). The presence of 
several bands in the Mono Q input lane most likely indicates the presence of several truncated 
variants of pUL98. Since pUL98, as identified by antibody specific to the protein, could be 
obtained using this procedure, this demonstrates that the protein bands in Figure 8A act as 
markers for the presence of pUL98. Though they do not have the correct apparent molecular 
weight, they are close in size and yield pUL98 when further purified by passage over the Mono 
Q column. 
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Figure 8 Tracking the Elution of Protein Using Coomassie Staining and Western Blots. A) The boxed region contains 2 
protein bands at 88 and 78 kDa. These bands were initially used as markers for putative pUL98 containing fractions. B) The red 
box indicates that the marker lane was being visualized despite the absence of His tags. The His antibody is not specific under the 
conditions used. C) The red box shows that the marker bands are not visualized when using the α-pUL98 antibody. The orange 
box contains signals indicating the presence of pUL98. 
 
 While Coomassie staining and Western blots had been used to track and identify those 
fractions containing pUL98 in early purifications, they could not determine whether or not the 
protein was active. Thus, a different assay was needed to test whether or not the pUL98 that was 
obtained still retained its nuclease function. The activity of various fractions was analyzed using 
the radioactivity release assay as described in the Materials and Methods. Initially, such an assay 
McKee 48 
 
was utilized to confirm which fractions contained active pUL98. However, the assay came to be 
used as another method of tracking the purification of pUL98 as it was sequentially passed over 
the Ni-chelating and Mono Q columns. Since the presumed relevant function of pUL98 is its 
nuclease activity, it was deemed more efficient to track the protein over the course of its 
purification using an assay that specifically indicates whether or not a fraction contains nuclease 
activity. Those fractions that contained the most activity could then be further analyzed via 
Western blots. The radioactivity assay, in combination with the pUL98-specific antibody 
Western blots, were key in deciding which fractions contained the protein of interest for both 
purification purposes and use in later experiments. 
 Figure 9 demonstrates the utility of the radioactivity release assay, both in identifying 
those fractions containing pUL98 activity as well as quantifying that activity. A representative 
selection of Mono Q fractions was assayed in Figure 9A, revealing the presence of a peak of 
maximal activity. There is a sharp increase in the activity of the fractions as the peak begins that 
trails in the later fractions. Identification of the relevant fractions narrowed down the range over 
which it was necessary to test for the presence of pUL98 by Western blot (Figure 9B). In 
addition to signals corresponding to pUL98, Figure 9B also contains signals that again indicate 
the presence of several truncated variants of pUL98.  
 Several key pieces of information were obtained by using and comparing radioactivity 
release assays and Western blots. First, nuclease activity corresponds directly with the presence 
of pUL98, and is not due to a contaminating factor. Such comparisons also validated the 
combined use of these two different methods to identify pUL98. Finally, it demonstrates that the 
presence of pUL98 as identified via Western blot does not necessarily mean that the fraction 
contains active pUL98. Thus, the use of the radioactivity release assay is necessary to identify 
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the fractions of interest. Such data can be observed by comparing Figure 9B to 9A. While 
fraction 25 contains both significant activity and immune-reactive pUL98 signal, fraction 22, 
which contains pUL98 signal, has less than half of the activity of the three most active fractions 
(23, 25, and 27). This demonstrates that the Western blot cannot be used alone to identify 
fractions of interest. It also demonstrates that there are fractions that contain what is thought to 
be full length pUL98 but have significantly lower activity than expected. This would result from 
inactivation of pUL98 so that it can no longer function appropriately, though the reason(s) for 
such a situation were not explored. 
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Figure 9 pUL98 Activity Compared to Mono Q Western Blots. Analyzing the elution fractions for the presence of pUL98 
activity indicates that those fractions with nuclease activity contain protein detectable by the α-pUL98 antibody. 
 
 
FRET Assay Design and Testing 
 While the radioactivity assay is effective in quantifying the activity of pUL98, it is not 
ideal for several reasons. It requires the use of radioactive substrate, which requires significant 
investments of time and resources to prepare and maintain. Such material also requires greater 
care and oversight when being used. Compounding this problem is the fact that relatively large 
amounts of substrate are necessary in the release assays. Measurement and quantification of the 
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results of such assays also requires significant investments of time, as a scintillation counting 
machine takes significantly more time to measure a sample than does a fluorimeter or a 
spectrometer. The relatively large volume of each reaction prohibits high throughput screening 
as well. 
 An alternative to the use of radioactive substrate in a release assay is the use of 
fluorescence resonance energy transfer (FRET) to quantify nuclease activity. FRET assays rely 
on the design of the substrate to work appropriately. When struck by light of the appropriate 
wavelength, a fluorophore absorbs the energy of the light and then emits light at a longer 
wavelength (lower energy) as excited electrons fall back to ground state. Chemical entities 
known as quenchers are capable of absorbing this emitted light when the quencher is in close 
proximity to the fluorophore. This relationship between fluorophore and quencher is critical in 
the use of a FRET assay. The substrate is designed in such a way that the quencher is kept nearby 
the fluorophore, preventing the emission of light. When the substrate is exposed to the protein of 
interest, in this case a nuclease, the fluorophore is cleaved and no longer in close proximity to the 
quencher. This allows the release of fluorescence that can then be detected via fluorimeter as a 
measurement of the activity of the nuclease. 
The design of the FRET assay used in my experiments is based off of prior work done by 
Allison Kuchta, a prior M.D./Ph.D. student from VCU who worked in the Parris lab. However, it 
was determined that the fluorescently labeled DNA substrate used in her assays was not ideal for 
my purposes for several reasons. In terms of design, the previous substrate relied on proximity 
and chemical affinity between the fluorophore and its quencher. This resulted in high levels of 
background fluorescence in the absence of any nuclease activity (data not shown). High 
background readings made it difficult to quantify the activity of pUL98, as the fluorescence 
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release quickly went beyond the linear range of the fluorimeter. Additionally, the design of the 
substrate was such that both exo and endonuclease activity could result in the detection of 
fluorescence. The main function of pUL98 is believed to be its exonuclease activity, due to 
significantly higher levels of this type of activity over endonuclease activity observed in previous 
experiments (31). The exonuclease activity of the pUL98 homolog, pUL12, has also been shown 
to be necessary for wild type viral production, as noted earlier (20, 22). Therefore, the 
exonuclease activity of pUL98 is the key function being analyzed in my experiments. Thus, the 
specificity of the substrate and what it measured was less than ideal, a problem which was 
exacerbated by the high levels of background fluorescence. 
I designed a new substrate for use in the following FRET assays that not only had 
significantly lower background, but also favored quantification of the exonuclease activity of 
pUL98 specifically (Figure 11). Figure 11A shows the design of the substrate, including both the 
sequence of the oligonucleotide as well as the locations of the various components specific to a 
FRET assay. Unlike the previous substrate, this one relies upon intramolecular base pairing to 
form a hairpin with a 5’ overhang that positions the fluorophore (FAM) in close proximity to the 
quencher (Iowa Black). Additionally, a proprietary compound known as Zen was utilized to 
further decrease the background fluorescence of the substrate (IDT). The formation of a hairpin 
also allows the substrate to favor exonuclease activity over endonuclease activity, as indicated by 
the mechanism of fluorescence release in Figure 11B. Though endonucleolytic cleavage can still 
occur, it is unlikely to cause the release of the fluorophore due to the base pairing present. 
Several endonucleolytic events would be needed to cause release of significant amounts of 
fluorescence. However, the FRET assays used were timed, thus allowing observation of the 
linear range of fluorescence release, which is consistent with exonuclease activity. Furthermore, 
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since the fluorophore is directly linked to the 5’ nucleotide, any exonuclease activity will result 
in the release of the fluorophore from the substrate, allowing detection of fluorescence.  
The conditions necessary for the FRET assay had to be determined over the course of 
several different experiments (data not shown). The correct concentration of substrate needed to 
be determined so that the fluorescence detected remained within the sensitive range of the 
instrument.  At the same time, enough substrate needed to be present to be able to accurately 
quantify the activity of pUL98. Time was another important factor, as the activity of pUL98 
needed to remain within the linear range of fluorescence release. Such conditions were 
elucidated by performing several variants of the FRET procedure in the Materials and Methods, 
where the effect of different variables was examined (different times, various substrate 
concentrations, etc.). This resulted in the FRET assay utilized in the following experiments and 
data. 
Figure 10 demonstrates the complete process from purification to FRET assay, as well as 
validates the proof-of-concept of the assay itself. Figures 10A and 10B show the Coomassie stain 
and corresponding Western blot for several of the Mono Q fractions. Those bands in the 
Coomassie stain that act as markers for the presence of pUL98 (as determined earlier) have 
apparent molecular weights between 96 and 103 kDa. The Western blot confirms the presence of 
pUL98 within these fractions, which were then assayed for nuclease activity using the 
radioactivity release assay (Figure 10C). A peak of activity, corresponding to fractions 25 and 
26, is observed and serves as the basis for using these fractions in the FRET assay in Figure 10D. 
Each fraction was assayed separately using the FRET assay, and a DNase I control was included. 
The activities of the Mono Q fractions were very similar, and significantly different from the 
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activity of the endonuclease DNase I. It appears that the linear range of fluorescence release for 
pUL98 occurs from 0 to 120 minutes at the concentrations tested. 
Significant activity of fractions 25 and 26 in both the FRET assay and the radioactivity 
release assay demonstrates the ability of these different assays to quantify nuclease activity—
nuclease activity in the radioactivity release assay corresponded to nuclease activity as 
determined via FRET assay. As expected, the pUL98-containing fractions displayed significantly 
greater activity in the FRET assay than did DNase I. Thus, the specificity of the timed assay for 
detecting exonuclease activity was validated. The elucidation of the linear range of fluorescence 
release was critical, as this information was necessary for later inhibition experiments. All 
inhibition experiments, as described in the Materials and Methods, were performed for no more 
than 75 minutes, and most were performed to a maximum of 60 minutes, well within the linear 
range of fluorescence release.  
The differences between the FRET assay and the radioactivity release assay demonstrate 
the favorability of the FRET assay. Significantly lower amounts of DNA substrate per amount of 
fraction material are required for the FRET assay while retaining the ability to effectively 
quantify pUL98 activity. Smaller reaction volumes allow for the screening of nuclease activity 
using 384 well plates, thus enabling a greater ability to assay pUL98 activity under different 
conditions and from different sources (fractions) in a lesser amount of time. A generally lesser 
amount of all reaction components means lower costs are required for the FRET assay. Such 
characteristics—lower cost, time, and materials combined with increased coverage—are needed 
for designing a high throughput assay to test inhibitors for their ability to inhibit the activity of 
pUL98.  
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Figure 10 Purification of pUL98 and Proof of Concept of the FRET Assay. A) The bands appearing between markers 100 
kDa and 70kDa have apparent molecular weights between 96 and 103 kDa. B) The presence of the bands in A) was used as a 
McKee 56 
 
marker for putative pUL98 containing fractions, as confirmed via α-pUL98 Western Blotting. C) Activity profile of the fractions 
identified in A) and B) demonstrating a peak of nuclease activity. D) Fractions 25 and 26 were determined to contain the greatest 
amount of active pUL98. These fractions were then used to demonstrate the validity and effectiveness of the FRET assay. 
 
 
 
Figure 11 FRET Assay Substrate and Detection of Activity.  
 
Inhibition Assays 
 With the proof-of-concept of the FRET assay complete, it was time to move onto the 
final phase of the process—the testing of different compounds for their effectiveness as 
inhibitors of pUL98. Through the use of in silico modeling and testing, collaborators at VCU 
were able to identify a set of compounds capable of interacting with the putative active site of 
pUL98. A subset of these compounds was sent to the Parris lab for testing and used in the newly 
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designed FRET assay. Through in vitro assays performed by VCU, it was determined that two 
compounds would be the focus of the FRET inhibition assays—Acid Blue 40 and Acid Blue 129 
(atanyl blue PRL). It was determined by VCU that Acid Blue 129 was more effective at 
inhibiting CMV than was Acid Blue 40, due to its lower EC50 (2). Acid Blue 129 was shown by 
our collaborators to inhibit CMV replication in cell culture, and that inhibition appears to occur 
at an early stage in the replication cycle (2). Though Acid Blue 40 had inhibitory effects on 
CMV, high concentrations that were similar to the cytotoxicity of the compound were required 
(2). These compounds, Acid Blues 40 and 129, are anthraquinone derivatives. As noted earlier, 
anthraquinone derivatives have been shown to have inhibitory effects against CMV in other 
studies. Since anthraquinone derivatives have activity against CMV, Acid Blue 129 appears to 
inhibit an early step in the replication cycle of CMV, pUL98 can be detected at early times post 
infection, and Acid Blue 129 has been proposed via in silico modelling to interact with the active 
site of pUL98, it was hypothesized that inhibition of pUL98 may be the mechanism by which 
inhibition of CMV replication in cell culture occurs. Thus, the results of FRET assay inhibition 
experiments could provide evidence of a) whether or not these compounds are inhibiting pUL98, 
b) the validity of the FRET assay, and c) the possibility of an early function for pUL98 in the 
viral life cycle. 
 Figure 12A shows data obtained from early inhibition experiments using the radioactivity 
release assay. The data indicates that pUL98 activity is inhibited by the presence of these 
putative inhibitory agents in the reaction mixture. In agreement with the findings of VCU, Acid 
Blue 129 was found to have a greater inhibitory effect than Acid Blue 40—the IC50 of Acid Blue 
129 was determined to be two orders of magnitude lower than the IC50 of Acid Blue 40 (6 vs 100 
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µM respectively). Figure 12B presents the same data and information that is in 12A, only in a 
different format. 
 These data indicated that further testing of the inhibitory compounds against pUL98 
using the FRET assay were both warranted and promising. It does appear that pUL98 is inhibited 
directly by these compounds, and thus provides evidence that this may be the mechanism of 
inhibition of CMV replication. As expected from the results provided by VCU, Acid Blue 129 
was more active against pUL98 than was Acid Blue 40. The presentation of the data in Figure 
12B allows for comparisons between inhibition studies using the radioactivity release assay and 
the FRET assay (Figure 12C). 
 Rather than compare the fluorescence detected for uninhibited pUL98 to that obtained 
using each concentration of inhibitor, it was decided that the rates of fluorescence release would 
be compared in the final assay. The variability in readings between independent replicates could 
potentially skew results. Thus, rather than look at absolute values of detected fluorescence, it is 
more accurate to look at the average rates of release as a metric of pUL98 activity. In order to do 
this, a time course was performed for each concentration of inhibitor, with time points taken at 
10, 30, and 45 minutes (well within the linear range determined in Figure 10D). From these data, 
a rate of fluorescence release by pUL98 activity was determined for each concentration and then 
compared to the maximum release rate (uninhibited pUL98). 
 The data from these FRET inhibition experiments is presented in Figure 12C. The format 
of these data is the same as the format of the radioactivity release data in Figure 12B. From these 
data, the IC50 of Acid Blue 129 is 9.3 µM while the IC50 of Acid Blue 40 is 149 µM. Both curves 
are representative of a standard dose response to the presence of increasing concentrations of 
inhibitor.  
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 As with the radioactivity assay and the preliminary results from VCU, Acid Blue 129 was 
found to have a greater inhibitory effect than Acid Blue 40. The IC50 values for both of these 
compounds were similar between the radioactivity release assay and the FRET assay—6 and 9.3 
µM for Acid Blue 129 and 100 and 149 µM for Acid Blue 40, respectively. Thus, the FRET 
assay is useful as both a method of screening for pUL98 activity as well as a platform with which 
to test the inhibitory effects of different compounds.  
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Figure 12 Inhibition of pUL98 Activity. A) Effects of various concentrations of each inhibitor on the activity of pUL98 as 
quantified using the radioactivity assay. Acid Blue 129 has a much lower IC50 (~6 µM) than does Acid Blue 40 (~ 100 µM). 
These results indicated that the compounds likely inhibit pUL98, and that further testing using the FRET assay was promising. B) 
The same data as presented in A), only this time matched to the same curve and layout as the FRET assay in C). C) Inhibition of 
pUL98 activity as quantified by the FRET assay. The IC50 for Acid Blue 129 is 9.3 µM while the IC50 for Acid Blue 40 is 149 
µM. B and C are adapted from Figure 6 in the Alam et al paper (2). 
 
Discussion and Future Work 
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 CMV is a ubiquitous viral pathogen capable of causing severe complications in infected 
individuals, particularly those who are immunocompromised. Current antiviral treatments are 
limited in nature due to their toxicities, side effects, and the emergence of drug resistant CMV 
strains. Thus, there is a need for new antiviral compounds that target viral machinery other than 
the viral DNA polymerase. This was the motivation behind the work presented here. Previous 
research on one of the proteins utilized by CMV, the alkaline nuclease pUL98, indicated that it 
may serve to be a promising target for antiviral therapy. The use of in silico modeling allowed a 
subset of potential inhibitory compounds to be isolated that may be active against pUL98. These 
compounds were subsequently tested for their effectiveness as inhibitors of the nuclease using 
two different assays. The FRET assay was designed in tandem with the testing of the compounds 
to create and optimize a system for high throughput testing of these compounds.  
 Two compounds, Acid Blues 129 and 40, were discovered to have inhibitory action 
against CMV at a step early in the viral life cycle, following entry of the virion into the host cell 
(2). One potential mechanism of inhibition at such a stage would be the inhibition of the activity 
of pUL98. This hypothesis was tested using purified nuclease in both radioactivity release and 
FRET assays. These assays indicated that the compounds did have inhibitory effects on pUL98, 
and that the concentrations observed to be effective at inhibiting UL98 enzyme activity were 
similar to those observed to inhibit the replication of CMV in cell culture (2).  
 One alternate possibility for the mechanism of inhibition of Acid Blues 129 and 40 is that 
they are intercalating into the substrate DNA due to their chemical nature, thus disrupting pUL98 
activity by disrupting its substrate. Such a mechanism would be devastating to a host if these 
compounds were to be used as antivirals. It is worth noting that the negative impact of 
intercalating agents on host cells may not be immediately apparent—such compounds can be 
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lethal, but they are also mutagenic, and could cause later effects. However, the data thus far do 
not support this possibility. In both types of assays, there is a typical inhibitory dose-response 
observed—as the concentration of inhibitor increases, the activity of pUL98 decreases in a 
typical dose-response fashion. If intercalation was the cause of this decrease, one would not 
expect to see this type of response to different concentrations of inhibitors. This is because a 
typical dose-response curve depends on the kinetics of the enzyme and interaction with the active 
site of said enzyme. With intercalation, there is no direct interaction between the pUL98 active 
site and the inhibitor—rather, the inhibition of activity would result from the inability of pUL98 
to interact with its substrate appropriately. The IC50 values for Acid Blue 129 were very similar 
when comparing the FRET inhibition assay to the radioactivity release inhibition assay—9.3 µM 
and 6 µM respectively. However, there was a much greater amount of DNA substrate present in 
the radioactivity release assay than in the FRET assay. Thus, if the inhibitor was functioning 
through intercalation, it would be expected that the IC50 for the radioactivity assay would be 
much higher than the value for the FRET assay, as a greater amount of inhibitor is needed to 
intercalate into the greater amount of DNA present. 
 The main function of pUL98 in viral replication may be its ability to act as an 
exonuclease, as indicated by previous research (31). The FRET assay developed was shown to be 
effective at not only characterizing the activity of pUL98, but at characterizing primarily the 
exonuclease activity of the protein. Any inhibition seen also indicated that the compound was 
preventing pUL98 from acting in this manner. Therefore, these results provide evidence that 
inhibition of the exonuclease activity of pUL98 is correlated with the inhibition of CMV seen in 
in vitro studies. 
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 Finally, the data provide clear proof-of-concept for the use of the FRET assay in studying 
the inhibitory effects of large numbers of potential antiviral compounds. Though only two 
compounds were tested, the design of the system allows for many replicates of many different 
inhibitors at many concentrations to be assayed. A high-throughput FRET assay would also use 
extremely small quantities of purified enzyme and DNA substrate and could be automated.  This 
can significantly increase the efficiency and speed with which potential antiviral compounds are 
identified and characterized. It is also possible that the assay could be altered to allow for the 
characterization of other nucleases, and the discovery of inhibitors for those pathogens utilizing 
them. 
 There are several avenues that have opened up as a result of this work. The optimal 
conditions for expression of pUL98 were not explicitly determined. Though the amount of 
protein obtained was sufficient for these experiments, an optimized method could result in 
significantly higher levels of protein. Additionally, such methods could be used at a larger scale 
to obtain enough protein for crystallography studies. No characterization was performed for 
pUL98 with the 2xHis tag cleaved from the N terminal end of the protein. Though cleavage of 
the tag was not necessary for the enzyme inhibition studies performed herein, it is not clear 
whether the tagged variant has significantly altered activity. Moreover, it would be important for 
starting material for crystallography studies to have the tag removed. In general, the 2xHis tag 
was not as useful as anticipated. Though it allowed for a first step purification using a Ni 
chelating column, it was not effective as a tag to be recognized by antibodies in Western blots. 
While I-2 α-pUL98 antibody was excellent for tracking the protein, its limited availability would 
preclude its routine use in pUL98 purification. There may exist a better way to tag and track the 
protein that does not rely on such a specialized antibody.  
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 There is more work to be done with respect to the inhibition of pUL98 and how it relates, 
if at all, to the inhibition of CMV in in vitro studies. In order to determine whether or not 
inhibition of pUL98 is the mechanism by which the virus is inhibited, mutant variants of virus 
resistant to Acid Blue 129 will need to be identified and isolated. The genomes of such mutants 
can then be sequenced, to see if any mutations conferring resistance correspond to changes in the 
gene for pUL98. If so, these mutant variants of pUL98 can be isolated and characterized for 
activity in the presence of inhibitor using the FRET assay. This is just one avenue that makes use 
of the assay designed in this research. 
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